Insurers cut GLP-1 access

Health plans across the U.S. have dropped or tightened coverage for Wegovy and Zepbound, cutting off millions of patients from obesity drugs that can cost about $1,000 a month without insurance. (nhpr.org) Prime Therapeutics, a pharmacy benefit manager that works with Blue Cross and Blue Shield plans, estimated about 12 million people lost coverage for Zepbound and another 12 million lost coverage for Wegovy after insurers changed formularies and prior-authorization rules. (nhpr.org) Wegovy is Novo Nordisk’s semaglutide, a glucagon-like peptide-1 drug that mimics a gut hormone to reduce appetite, and the Food and Drug Administration approved it for chronic weight management and for reducing major cardiovascular events in some adults with obesity or overweight. (fda.gov) Zepbound is Eli Lilly’s tirzepatide, which targets both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, and the Food and Drug Administration approved it for long-term weight reduction in adults with obesity or overweight plus a related condition. (fda.gov) Insurers and employers have argued that demand for these drugs rose faster than budgets could absorb, and state Medicaid programs have also pulled back because of projected costs. New Hampshire ended Medicaid coverage for weight-loss GLP-1 drugs on January 1, 2026, after estimating it would cost tens of millions of dollars a year to restore broad coverage. (nhpr.org; nhpr.org) Doctors and patients say the cutbacks are disrupting treatment for a chronic disease that often returns when medication stops. Dartmouth Health obesity specialist Sarah Finn told NHPR she has seen patients regain weight and lose control of related conditions after coverage ended. (nhpr.org) Some patients are switching to older, less effective drugs, spacing out doses, or quitting treatment entirely. Others are turning to compounded versions even after the Food and Drug Administration said shortages of Wegovy and Zepbound had ended and compounders were supposed to stop making copies tied to those shortages. (nhpr.org; npr.org) The coverage fight is also exposing a split in how obesity is treated in insurance design. Many plans still cover GLP-1 drugs for diabetes, and Wegovy also has a cardiovascular-risk indication, but broad coverage for obesity alone remains uneven across commercial insurance, Medicare, and Medicaid. (fda.gov; nhpr.org) For patients who had finally found a drug that worked, the practical question is no longer whether these medicines can help. It is whether their next refill will still be covered. (nhpr.org)